PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: This study aims to compare the efficacy of docetaxel on PSA levels and to analyze the adverse events caused by docetaxel. Material & Methods: The study design was retrospective cohort. Participants were prostate cancer patients at Saiful Anwar Hospital who received androgen deprivation therapy with increased PSA level 3 times the nadir or 2 bone lesions or soft tissue lesions > 2cm. PSA levels were assessed monthly. Participants were grouped into 6 and 10 series regimens. Adverse events of nausea, diarrhea, alopecia, SGOT SGPT abnormailties, creatinine abnormalities, anemia, and neutropenia were observed. Statistical analysis was performed using a differential T-test. Results: A total of 32 participants were involved. The PSA levels between 6 and 10 series groups were as follows: 1st month (142.2 vs 28.24 ng/mL,p=0.000), 2nd month (101.78 vs 16.98 ng/mL,p=0.001), 3rd month (472.35 vs 13.95 ng/mL,p=0.439), 4th month (120.64 vs 4.0 ng/mL,p=0.180), 5th month (64.325 vs 24.6 ng/mL, p=0.015), 6th month (41.915 vs 20.7 ng/mL,p=0.497). Adverse events in the 6 and 10 series regimens were nausea (25% vs 81.25%), diarrhea (37.5% vs 50%), alopecia (6.25% vs 43.75%), SGOT SGPT abnormalities (25% vs 56.25%), creatinine abnormalities (6.25% vs 37.5%), anemia (18.75% vs 31.25%), leukocytosis (6.25% vs 0%), and neutropenia (25% vs 12.5%). Adverse events in 6 series regimen began to occur in 3rd series with 1 participant experiencing nausea, and the most were 3 participants experiencing diarrhea in 6th series. Adverse events in 10 series regimen began to occur in 4th series with 1 participant experiencing nausea, 1 participant experiencing SGOT SGPT abnormalities, 1 participant experiencing diarrhea, and the most were 4 participants experiencing nausea in the 9th series. Conclusion: The 10 series of docetaxel chemotherapy is not superior to 6 series. Adverse events are more prominent in the 10 series. Keywords: Docetaxel, PSA, adverse events.
##plugins.themes.bootstrap3.article.details##
Docetaxel, PSA, adverse events.
Leslie, S. W., Soon-Sutton, T. L., Sajjad, H. and Siref, L. E. Prostate Cancer. Genomic and Precision Medicine: Oncology. Third Edition. 2022. pp. 277–284.
Rawla, P. Epidemiology of Prostate Cancer. World Journal of Oncology. 2019; 10(2): 63.
Gondhowiardjo, S. et al. Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia. JCO Global Oncology. 2021; 7: 190–203.
Descotes, J. L. Diagnosis of prostate cancer. Asian Journal of Urology. 2019; 6(2): 129–136.
Azarenko, O., Smiyun, G., Mah, J., Wilson, L. and Jordan, M. A. Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. Molecular Cancer Therapeutics. 2014; 13(8): 2092–2103.
Oudard, S. et al. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-Risk Prostate Cancer with Rising Prostate-Specific Antigen Levels after Primary Local Therapy: A Randomized Clinical Trial. JAMA Oncology. 2019; 5(5): 623–632.
Ho, M. Y. and Mackey, J. R. Presentation and management of docetaxel-related adverse events in patients with breast cancer. Cancer Management and Research. 2014; 6(1): 253–259.
Omlin, A. et al. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated with Docetaxel and Cabazitaxel. Clinical Genitourinary Cancer. 2015; 13(4): e205–e208.
Francini, E., Petrioli, R., Rossi, G., Laera, L. and Roviello, G. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. Tumor Biology. 2014; 35(11): 10601–10607.
Burtness, B. et al. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. American Journal of Clinical Oncology: Cancer Clinical Trials. 2016; 39(4): 340–345.
Pelosof, L. et al. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer. International Journal of Cancer. 2014; 134(3): 596–605.
Fizazi, K., Jenkins, C. and Tannock, I. F. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Annals of Oncology. 2015; 26(8): 1660–1667.
Miles, D. et al. Effect of docetaxel duration on clinical outcomes: Exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Annals of Oncology. 2017; 28(11): 2761–2767.
Nelius, T. and Filleur, S. PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. Prostate. 2009; 69(16): 1802–1807.
Cao, J. Z., Pan, J. F., Ng, D. M., Ying, M. Q., Jiang, J. H. and Ma, Q. Maintenance long-term multiple cycles treatment with docetaxel in metastatic castration-resistant prostate cancer: A report of three cases. OncoTargets and Therapy. 2021; 14: 2797–2803.
Nakai, Y., Tanaka, N., Ichikawa, K., Miyake, M., Anai, S. and Fujimoto, K. Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control. Chemotherapy. 2021; 65(5–6): 119–124.
Kato, S. et al. Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. Scientific World Journal. 2021; 1.
Pond, G. R. et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. European Urology. 2012; 61(2): 363–369.
Shen, Y. C. et al. Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer. Kaohsiung Journal of Medical Sciences. 2016; 32(9): 458–463.
De Morrée, E. S. et al. Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: A post hoc analysis of the Mainsail study. JAMA Oncology. 2017; 3(1): 68–75.
Takahashi, M. et al. Long-Term Administration of Docetaxel over 70 Cycles for Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 2015; 13(4): e337–e340.